NCT06283550 - Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

November 14, 2025

Study Completion Date

December 31, 2025

Conditions

Chronic Hand Eczema

Interventions

DRUG

Abrocitinib 200 mg

Abrocitinib will be available in 100 mg strength tablet

DRUG

Abrocitinib 100 mg

Abrocitinib will be available in 100 mg strength tablet

DRUG

Placebo

Placebo tablet

Trial Locations (12)

INNO-6052 Site 12, Fredericton

INNO-6052 Site 13, Cobourg

INNO-6052 Site 11, Montreal

INNO-6052 Site 19, Krakow

INNO-6052 Site 17, Lodz

INNO-6052 Site 21, Lublin

INNO-6052 Site 23, Mikołów

INNO-6052 Site 18, Osielsko

INNO-6052 Site 15, Pomorskie

INNO-6052 Site 20, Szczecin

INNO-6052 Site 16, Warsaw

INNO-6052 Site 22, Wroclaw